Repligen makes equipment for manufacturing biologic drugs.
Repligen Corporation (RGEN) is expected to report earnings on Tuesday, October 27, 2026, before the open. Estimated release time 07:33 ET. Consensus EPS estimate is $0.46.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-07-29 | Jun 2026 qtr | $0.45 | $0.54 | — | $204.13M |
| 2026-05-06 | Mar 2026 qtr | $0.38 | $0.48 | — | $194.25M |
| 2026-02-26 | Dec 2025 qtr | $0.44 | $0.49 | +11.4% | $197.91M |
| 2025-11-04 | Sep 2025 qtr | $0.42 | $0.46 | +9.5% | $188.81M |
| 2025-08-07 | Jun 2025 qtr | $0.40 | $0.37 | -7.5% | $182.37M |
| 2025-04-29 | Mar 2025 qtr | $0.35 | $0.39 | +11.4% | $169.17M |
| 2025-03-14 | Dec 2024 qtr | — | $-0.60 | — | $167.55M |
| 2024-11-18 | Sep 2024 qtr | $0.34 | $0.32 | -4.6% | $154.87M |
RGEN has beaten consensus EPS in 3 of its last 5 scored quarters.
See RGEN on the live calendar →